Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07177339 · ClinicalTrials.gov registry record · Phase 3
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
A Phase 3 study of Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,196
- Enrollment target
- 6
- Study locations
NCT07177339 is a Phase 3 study of Pulmonary Disease, Chronic Obstructive that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 1,196 participants, above the 1,028-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (16% higher). The trial reports 6 study locations across 2 states.
The verdict
NCT07177339, a Phase 3 study of Pulmonary Disease, Chronic Obstructive, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,196 participants
- Enrollment target
- 6
- Study locations
Study Summary
Depemokimab is being developed as a treatment for individuals with moderate to severe Chronic Obstructive Pulmonary Disorder (COPD). The aim of this study is to assess the efficacy and safety of early initiation of depemokimab as an add-on medicine in participants with moderate to severe COPD with type 2 inflammation.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Depemokimab
Study Locations (6)
Other
- GSK Investigational Site - Chengdu
- GSK Investigational Site - Guilin
- GSK Investigational Site - Jiangmen
- GSK Investigational Site - Nanchang
- GSK Investigational Site - Taizhou
Florida
- GSK Investigational Site - Doral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,196 participants |
| Start Date | 2025-10-20 |
| Est. Completion | 2029-12-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07177339
The ClinicalTrials.gov registry entry for NCT07177339 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,196 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,028-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (16% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07177339 reports 6 study locations spanning 2 distinct geographic areas - top geographies include Other, Florida.
Frequently Asked Questions
What is clinical trial NCT07177339 about?
NCT07177339 is a clinical study titled "eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation". Depemokimab is being developed as a treatment for individuals with moderate to severe Chronic Obstructive Pulmonary Disorder (COPD). The aim of this study is to assess the efficacy and safety of early initiation of depemokimab as an add-on medicine in participants with moderate to severe COPD with t...
What is the current status of trial NCT07177339?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,196 participants. The study started on 2025-10-20. Estimated completion is 2029-12-14.
What conditions does trial NCT07177339 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT07177339?
The interventions under investigation include: Placebo (DRUG), Depemokimab (DRUG).
Who is sponsoring clinical trial NCT07177339?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07177339 being conducted?
This trial has 6 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
RECRUITING · Phase 3
-
Trial to Determine Effective Aspirin Dose in COPD
RECRUITING · Phase 3
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
RECRUITING · Phase 3
-
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B
COMPLETED · Phase 3
-
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 3
-
Tiotropium / Respimat One-Year Study
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.